Zevalin and Extravasation - a phase IV clinical study of FDA data

Summary:

Extravasation is reported as a side effect among people who take Zevalin (ibritumomab tiuxetan), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Bicnu, and have Mantle cell lymphoma stage iv.

The phase IV clinical study analyzes which people have Extravasation when taking Zevalin. It is created by eHealthMe based on reports of 2,256 people who have side effects when taking Zevalin from the FDA, and is updated regularly.

What is Zevalin?

Zevalin has active ingredients of ibritumomab tiuxetan. eHealthMe is studying from 2,258 Zevalin users. Check the latest studies of Zevalin.

What is Extravasation?

Extravasation (leakage of a fluid) is found to be associated with 256 drugs and 490 conditions by eHealthMe. Check the latest studies of Extravasation.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

2,256 people reported to have side effects when taking Zevalin.
Among them, 14 people (0.62%) have Extravasation.

Among these 14 people:

How long have people been on Zevalin when they have Extravasation? *

What is the gender of people who have Extravasation when taking Zevalin? *

female: 0.0 %
male: 100 %

What is the age of people who have Extravasation when taking Zevalin? *

What are other drugs people take besides Zevalin? *

What are other side effects people have besides Extravasation? *

Skin Swelling: 12 people, 85.71%
Skin Necrosis (skin damage): 12 people, 85.71%
Rashes (redness): 12 people, 85.71%
Pain: 12 people, 85.71%
Injection Site Reaction: 12 people, 85.71%
Radiation Injury (injuries are caused by radiation): 11 people, 78.57%
Joint Range Of Motion Decreased (disease of joint movement): 10 people, 71.43%
Radiation Skin Injury: 8 people, 57.14%
Malignant Neoplasm Progression (cancer tumour came back): 1 person, 7.14%
Blood Lactate Dehydrogenase Increased: 1 person, 7.14%

What are the existing conditions these people have? *

Mantle Cell Lymphoma Stage Iv (cancer of lymphocytes, a type of white blood cell, spreads to other part of body): 12 people, 85.71%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Zevalin and have Extravasation?

- Check whether Extravasation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zevalin:

Zevalin (2,258 reports)

Extravasation treatments and more:

Extravasation (4,227 reports)

Browse all side effects of Zevalin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Extravasation:

Extravasation (256 drugs)

Browse all the conditions that are associated with Extravasation:

Extravasation (490 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ibritumomab tiuxetan (the active ingredients of Zevalin) and Zevalin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.